In the United States, only people with certain medical conditions at higher risk of developing severe COVID-19 are currently eligible to receive the drug. Now, a new study suggests that expanding eligibility to include all people with COVID-19 could benefit everyone. Canadian researchers studied 41 trials that covered more than 18,000 people with non-severe COVID-19. They reported […]
